Pneumococcal polysaccharide vaccine responses are impaired in a subgroup of children with cystic fibrosis.
J Cyst Fibros
; 13(6): 632-8, 2014 Dec.
Article
em En
| MEDLINE
| ID: mdl-24636807
ABSTRACT
BACKGROUND:
Pneumococcal immunization is recommended in children with cystic fibrosis (CF). To date, however, there are no published studies on the efficacy of pneumococcal vaccination in this group of patients.METHODS:
We carried out a retrospective study of serotype-specific pneumococcal antibody responses to immunization with Prevenar 7 and Pneumovax II in a cohort of children with CF.RESULTS:
Nine children had been immunized with Prevenar 7, and all had serotype-specific pneumococcal antibody levels in the protective range (>0.35mg/L) to all 7 immunizing serotypes. In contrast, only 7 of 33 patients (21%) immunized with Pneumovax II made protective antibody responses to all 7 serotypes, and 3 failed to make protective antibodies to any of the serotypes. Controlling for age as a confounder in the analysis, children with impaired antibody responses to pneumococcal polysaccharide (Pneumovax II) immunization had lower Shwachman-Kulczycki scores than children with normal polysaccharide antibody responses. All isolates of Pseudomonas aeruginosa occurred in patients with impaired anti-pneumococcal antibody responses, and a broader range of respiratory pathogens was isolated from these children.CONCLUSIONS:
Impaired antibody responses to immunization with Pneumovax II are common in children with CF and this may be associated with increased disease severity.Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Infecções Pneumocócicas
/
Streptococcus pneumoniae
/
Vacinas Pneumocócicas
/
Fibrose Cística
/
Anticorpos Antibacterianos
Idioma:
En
Ano de publicação:
2014
Tipo de documento:
Article
País de afiliação:
Reino Unido